Bevacizumab in advanced prostate cancer

Drug Management of Prostate Cancer

Volumn , Issue , 2010, Pages 207-214

  Elfiky, Aymen A ^b   Kelly, William Kevin ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Bevacizumab; Drugs; Prostate cancer

Indexed keywords

EID: 80054980624     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-829-4_18     Document Type: Chapter

References (45)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
2. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothe-lial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
3. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79: 185-8.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
5. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-16.
6. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975;82:96-100.
7. Wray CJ, Rilo HL, Ahmad SA. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 2004;13:631-41.
8. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69-71.
9. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-6.
10. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new signifcant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
11. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angio-genesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
12. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
13. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545-51.
14. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001;86:23-33.
15. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13:31-6.
16. Gerber HP, Ferrara N. Pharmacology and pharmacodynam-ics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671-80.
17. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
18. Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than antiangiogenic. Cancer Metastasis Rev 2007;26: 443-52.
19. Ferrara N. Role of vascular endothelial growth factor in regulation of angiogenesis. Kidney Int 1999;56:794-814.
20. Ferrara N and Davis-Smyth T. The biology of vascular endothelial growth factor. Endrocrinology 1997;18:1-22.
21. Ferrer FA, Miller LJ, et al. Expression of vascular endothelial receptors inhuman prostate cancer. Urology 1999;43:567-72.
22. Ferrer FA, Miller LJ, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of FEGG by human prostate cancer cells. J Urol 1997;157:2329-33.
23. Duque J, Loughlin K, et al. Plasma levels of vascular endothelial growth factor are increased in patients with met-astatic prostate cancer. Urology 1999;45:523-27.
24. Duque JL, Loughlin KR, et al. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specifc antigen. Clinics 2006;61(5):401-8.
25. Bok R, Halabi S, et al. VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study. Cancer Res 2001;61:2533-6.
26. George D, Halabi S, et al. Prognostic signifcance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone refractory prostate cancer: a CALGB study. Clin Cancer Res 2001;7:1932-6.
27. Joseph IBJK, Nelson JB, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostate tissues. Clin Cancer Res 1997;3:2507-11.
28. Jain A, Safabakhsh N, et al. Endothelial cell death, angiogen-esis, and microvascular function after castration in an andro-gen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998;95:10820-25.
29. Kirschenbaum A, Wang J, et al. Inhibition of vascular endothelial cell growth factor suppresses the in vitro growth of human prostate cancer tumors. Urol Oncol 1997;3:3-10.
30. Borgstrom P, Bourdon M, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro-tumors in vivo. Prostate 1998;35:1-10.
31. Melynk O, Simmerman M, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in pre-clinical model. J Urol 1999;161:960-63.
32. Hammarsten P, Halin S, et al. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006;12(24):7431-6.
33. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. Bevacizumab plus irinotecan, fuorou-racil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
34. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO 2005 (abstract 2).
35. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50.
36. Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as frst-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94 (suppl 1):S6 (abstract 3).
37. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-99.
38. Reese DM, Fratesi P, Corry M, et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate 2001;3:65-70.
39. Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22:1578.
40. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a fnal report of CALGB 9780. J Clin Oncol 2001;19(9):2509-16.
41. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 2003;98(12):2592-8.
42. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089-94.
43. Ning YM, Gulley JL, Arlen PM, et al. A phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070-6.
44. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, predni-sone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. ASCO Annual Meeting Proceedings J Clin Oncol 2010;28:LBA4511.
45. Keating NL, O'Malley AJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56.